Bet v 1.0101, Sf9

The Major Pollen Allergen Bet v 1-A is a significant allergen derived from birch pollen (Betula verrucosa). It is known to cause type I allergic reactions, particularly in Europe, North America, and the former Soviet Union states, typically observed in early spring . The recombinant form of this allergen, produced in Sf9 insect cells, is utilized for various research and diagnostic purposes.

The recombinant Major Pollen Allergen Bet v 1-A is produced using the Sf9 insect cell expression system. Sf9 cells, derived from the fall armyworm (Spodoptera frugiperda), are commonly used for the production of recombinant proteins due to their ability to perform post-translational modifications, such as glycosylation, which are essential for the proper folding and functionality of many proteins .

The recombinant Bet v 1-A allergen is a glycosylated polypeptide chain with a calculated molecular mass of approximately 18.5 to 18.9 kDa . It consists of 167 amino acids and is often expressed with a His-tag at the N-terminus to facilitate purification . The protein is typically supplied in a sterile filtered clear solution and formulated in buffers such as HEPES or PBS to maintain stability .

Recombinant Bet v 1-A is primarily used in allergy research and diagnostics. It binds to IgE antibodies in human sera, making it valuable for immunodot tests and other diagnostic assays . The recombinant form allows for consistent and controlled studies, which are crucial for understanding the allergenic properties and developing potential treatments or preventive measures.

The stability of the recombinant Bet v 1-A allergen is maintained by storing it at 4°C for short-term use (2-4 weeks) or at -20°C for long-term storage. It is important to avoid multiple freeze-thaw cycles to preserve the protein’s integrity and functionality .